Top Page
bioAffinity Technologies, Inc.
(NASDAQ:BIAF)
bioAffinity Technologies, Inc. (BIAF) vs. SPDR S&P 500 ETF (SPY)
bioAffinity Technologies, Inc. Business Overview & Revenue Model
bioAffinity Technologies, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.78M | 9.36M | 2.53M | 4.80K | 0.00 | 0.00 |
| Gross Profit | 1.62M | 3.38M | 791.62K | 4.34K | -4.82K | -22.24K |
| EBITDA | -14.11M | -8.33M | -7.63M | -5.61M | -5.32M | -6.86M |
| Net Income | -14.74M | -9.04M | -7.94M | -8.15M | -6.33M | -7.27M |
Balance Sheet | ||||||
| Total Assets | 11.55M | 6.51M | 8.22M | 12.18M | 1.45M | 145.60K |
| Cash, Cash Equivalents and Short-Term Investments | 7.67M | 1.11M | 2.82M | 11.41M | 1.36M | 83.11K |
| Total Debt | 680.95K | 1.50M | 1.58M | 251.75K | 11.36M | 10.01M |
| Total Liabilities | 2.64M | 3.91M | 3.37M | 1.14M | 17.24M | 15.22M |
| Stockholders Equity | 8.90M | 2.60M | 4.86M | 11.04M | -15.79M | -15.07M |
Cash Flow | ||||||
| Free Cash Flow | -8.51M | -7.34M | -6.06M | -4.29M | -2.05M | -2.21M |
| Operating Cash Flow | -8.45M | -7.26M | -6.04M | -4.07M | -2.05M | -2.21M |
| Investing Cash Flow | -60.57K | -79.08K | -2.21M | -219.99K | 0.00 | -2.89K |
| Financing Cash Flow | 15.42M | 5.63M | -344.98K | 14.34M | 3.33M | 1.72M |
bioAffinity Technologies, Inc. Technical Analysis
bioAffinity Technologies, Inc. Risk Analysis
bioAffinity Technologies, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $5.52M | -3.09 | -223.45% | ― | 3.26% | 65.96% | |
41 Neutral | $9.61M | ― | ― | ― | ― | ― | |
41 Neutral | $3.63M | -0.05 | -296.20% | ― | -67.73% | 58.35% | |
38 Underperform | $5.71M | -0.06 | -245.18% | ― | -27.66% | 13.18% | |
34 Underperform | $6.09M | -0.38 | -236.34% | ― | ― | 98.86% |
bioAffinity Technologies, Inc. Corporate Events
On December 19, 2025, bioAffinity Technologies, Inc. convened but immediately adjourned a special meeting of stockholders after failing to reach a quorum, as an insufficient number of common shares were present in person or by proxy to conduct business. The special meeting has been rescheduled to reconvene on January 19, 2026, with the November 4, 2025 record date and all voting proposals unchanged, and previously submitted proxies remaining valid unless stockholders choose to alter their votes through the available proxy voting channels.
On December 3, 2025, bioAffinity Technologies announced that it will present a poster at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025. The poster highlights the successful use of CyPath® Lung, a noninvasive sputum-based flow cytometry test, in identifying Stage 1A lung cancer in patients with atypical presentations. This development underscores the test’s potential to provide clarity in complex diagnostic scenarios, potentially reducing the need for invasive procedures and improving early-stage lung cancer diagnosis.
On November 5, 2025, bioAffinity Technologies announced significant growth in the volume of their CyPath® Lung tests, with October’s test volume showing a 111% increase over the 2025 monthly average. This growth reflects the increasing recognition of the test’s clinical value by physicians and the success of the company’s outreach efforts to healthcare providers. The steady adoption of CyPath® Lung is seen as a step towards changing the standard of care in early lung cancer detection.
On October 28, 2025, bioAffinity Technologies announced that the Australian Patent Office accepted its patent application for a platform technology to assess lung health and predict multiple lung diseases. This acceptance strengthens bioAffinity’s global patent portfolio, enhancing its market positioning and protecting its core technology, which is crucial for the CyPath® Lung test and other diagnostics in development.
On October 20, 2025, bioAffinity Technologies announced its participation in CHEST 2025, where they will present research supporting the CyPath® Lung test’s methods for collecting and transporting patient samples. The study highlights the test’s ability to detect early-stage lung cancer with high sensitivity and specificity, potentially improving patient outcomes.
On October 16, 2025, bioAffinity Technologies, Inc. announced it received a notification of allowance from the United States Patent and Trademark Office for a patent titled ‘Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning.’ This patent covers a system and method for predicting lung cancer by analyzing patient sputum samples using an AI-built algorithm and flow cytometry platform. This development enhances bioAffinity’s intellectual property portfolio, which includes 18 awarded and 33 pending patents globally, and reinforces its position in the early-stage cancer diagnostics industry. The CyPath® Lung test, integral to this patent, offers high sensitivity and specificity in detecting early-stage lung cancer, potentially improving patient outcomes and reducing healthcare costs.
On October 15, 2025, bioAffinity Technologies announced it has regained compliance with Nasdaq’s listing requirements, ensuring its common stock and warrants continue trading on the Nasdaq Capital Market. This compliance allows the company to focus on advancing its CyPath® Lung test and broader diagnostic pipeline, while a mandatory one-year panel monitor will oversee adherence to the equity rule, with potential delisting if compliance is not maintained.
On October 8, 2025, bioAffinity Technologies, Inc. announced a securities purchase agreement with institutional investors for a registered direct offering of 720,000 shares of common stock, which closed on October 9, 2025, raising approximately $1.8 million. The proceeds are intended to support working capital, growing sales for CyPath® Lung, and general corporate purposes, with WallachBeth Capital, LLC acting as the sole placement agent. The company has agreed to certain restrictions on issuing additional shares and entering variable rate transactions until specified dates, impacting their operational flexibility and market strategy.
On October 7, 2025, bioAffinity Technologies announced a significant increase in sales of its CyPath® Lung diagnostic test for lung cancer, with a 95% rise in the third quarter of 2025 compared to the previous quarter. This growth is attributed to increased adoption by Veterans’ hospitals and expansion in the mid-Atlantic region. The test’s ability to detect early-stage lung cancer and prevent unnecessary invasive procedures has boosted physician confidence and integration into clinical practice, leading to a 77% increase in new patient usage. The company’s advancements highlight its strengthening position in the diagnostic market and its positive impact on patient care.
On September 29, 2025, bioAffinity Technologies, Inc. completed a public offering of common stock and pre-funded warrants, raising approximately $4.8 million. The proceeds are intended for working capital and general corporate purposes. The company has entered into agreements restricting further issuance of shares for a certain period, aiming to stabilize its market position. Additionally, bioAffinity Technologies has been working to regain compliance with Nasdaq’s listing requirements, including implementing a reverse stock split to meet the Minimum Bid Price Requirement. The company has made significant progress in addressing these compliance issues, including increasing its stockholders’ equity and eliminating certain liabilities.